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Introduction
Spontaneous preterm labour is a major cause of preterm birth
(37/40 weeks of gestation). Preterm births account for ~6–7%
of all deliveries in developed countries and up to 25% in undevel-
oped nations. In the developed world, approximately 75% of
neonatal deaths and a majority of neonatal intensive care admis-
sions, arise from preterm babies born before 32 weeks of gesta-
tion [1]. In addition, the short- and long- term economic conse-
quences of preterm birth are considerable [2, 3].
Clinical management strategies for women at risk of preterm
labour are restricted as women cannot currently be identified
accurately from the antenatal population. As a result, most women
present in threatened preterm labour requiring tocolytic (agents
that inhibit uterine contractions) treatment. However, the tocolyt-
ics currently employed clinically (oxytocin receptor antagonists,
2 mimetics and nifedipine) provide only limited benefit either in
prevention of labour or in regard to neonatal outcome [4].
Development of more effective tocolytic therapies would have
major benefits for maternal and neonatal health worldwide and
lead to substantive reductions in health care costs.
Improved understanding of the processes responsible for
suppressing myometrial (uterine smooth muscle) contractility
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Abstract
Premature birth accounts for approximately 75% of neonatal mortality and morbidity in the developed world. Despite this, methods for
identifying and treating women at risk of preterm labour are limited and many women still present in preterm labour requiring tocolytic
therapy to suppress uterine contractility. The aim of this study was to assess the utility of Kv7 channel activators as potential uterine
smooth muscle (myometrium) relaxants in tissues from pregnant mice and women. Myometrium was obtained from early and late preg-
nant mice and from lipopolysaccharide (LPS)-injected mice (day 15 of gestation; model of infection in pregnancy). Human myometrium
was obtained at the time of Caesarean section from women at term (38–41 weeks). RT-PCR/qRT-PCR detected KCNQ and KCNE expres-
sion in mouse and human myometrium. In mice, there was a global suppression of all KCNQ isoforms, except KCNQ3, in early preg-
nancy (n  6, P  0.001 versus late pregnant); expression subsequently increased in late pregnancy (n  6). KCNE isoforms were also
gestationally regulated (P  0.05). KCNQ and KCNE isoform expression was slightly down-regulated in myometrium from LPS-treated-
mice versus controls (P  0.05, n  3–4). XE991 (10 M, Kv7 inhibitor) significantly increased spontaneous myometrial contractions
in vitro in both human and mouse myometrial tissues (P  0.05) and retigabine/flupirtine (20 M, Kv7 channel activators) caused pro-
found myometrial relaxation (P  0.05). In summary, Kv7 activators suppressed myometrial contraction and KCNQ gene expression
was sustained throughout gestation, particularly at term. Consequently, activation of the encoded channels represents a novel mecha-
nism for treatment of preterm labour.
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during normal pregnancy will inevitably inform development of
effective therapeutic strategies. Potassium channel expression
and function is particularly relevant as these channels are major
contributors to the resting membrane potential, thereby influ-
encing cell excitability and repolarization in the smooth muscle
of the myometrium. In human myometrial smooth muscle, the
resting membrane potential becomes less negative toward the
end pregnancy and labour onset [5] and this is likely to be driven
in part by down-regulation of (functional) potassium (K) chan-
nels [6, 7]. We have shown that voltage-dependent K channels
encoded by the ‘ether–a-go-go related’ gene (KCNH1) become
functionally redundant at the end of mouse pregnancy due to up-
regulation of accessory  subunits [8]. Paradoxically, however,
we and others have also demonstrated that voltage-dependent
(Kv) channels in general still play a key role in rat and murine
myometrium at term [9, 10]. The conclusion, therefore, is that
subsets of Kv channels exist to enable repolarization and
myometrial relaxation during the rhythmic contractile activity
associated with labour [7, 11]. These Kv channel subtypes rep-
resent novel targets for tocolysis as expression in myometrium
is coincidental with the time of labour.
Recent studies from our laboratory in murine myometrium
indicate that expression of KCNQ (-subunits) and KCNE (-sub-
units) genes, which encode Kv7 channels, are modulated during
the oestrous cycle [12] where they contribute to non-pregnant
mouse myometrial contractility. The aim of the present study was
to establish the expression and function of myometrial Kv7 chan-
nels during pregnancy in mouse and human myometrium and,
with a view to development of new tocolytic strategies, to deter-
mine whether Kv7 channel activators act as uterine relaxants at
term. To address their potential role in infection associated
preterm labour and to establish the influence of infection on
KCNQ/KCNE expression, an intraperitoneal model of lipopolysac-
charide (LPS)-induced preterm labour was utilized. This model
induces a systemic inflammatory reaction and shares many of the
characteristics of the inflammatory response associated with
infection in human preterm labour [13].
Materials and methods
All reagents were supplied by Sigma-Aldrich (Gillingham, UK) unless oth-
erwise stated in the text.
Tissue collection
Time-mated mice
Female C57/BL6 mice (Charles River Laboratories, Margate, UK) were
killed by cervical dislocation, in accordance with UK Home Office guide-
lines, in early (days 6–7) and late pregnancy (days 17–18). Uterine horns
were dissected, opened longitudinally and foetuses/placentae removed.
The decidua/endometrium was then gently removed using a cotton bud.
Myometrium was dissected and either immediately snap frozen in liquid
nitrogen for RNA and protein isolation and stored at 80	C or placed
straight into ice cold phosphate-buffered saline (PBS, Sigma-Aldrich) for
isometric tension recording. Samples for RNA extraction were later trans-
ferred to RNAlaterICE (according to manufacturers recommendations:
Ambion, Warrington, UK).
Lipopolysaccharide treated mice
C57/BL6 mice (8 weeks, n  6) were mated during 2 hr time periods.
Day 0 was determined by visualization of copulatory plug and on the 15th
day of pregnancy, mice were injected intraperitoneally with 100 g LPS
from Escherichia coli, serotype 0111:B4 (Sigma, St. Louis, MO, USA) in
sterile saline (n  4) or with vehicle alone (n  3). Mice injected with LPS
delivered approximately 16 hrs after injection if left undisturbed (data not
shown, [14]), but for the present study mice were killed by CO2 inhalation
8 hrs after injection for myometrium mRNA analysis. The uterus was dis-
sected and the number of foetuses within the uterus or birth canal
recorded. Foetuses and foetal membranes were removed and
myometrium snap frozen in liquid nitrogen and stored at 80	C.
Human myometrial tissue
Myometrium was obtained, with informed written consent, from women
undergoing Caesarean section at term (
37 weeks; n  9) not in labour,
as approved by the Guy’s and St Thomas’ Ethics Committee (EC00/137).
Biopsies were obtained from the upper edge of the lower segment incision
and placed into ice-cold PBS. The tissue was immediately dissected in a
sterile Petri dish on ice into small segments and then either snap frozen for
RNA extraction or longitudinal muscle strips placed in ice-cold PBS for iso-
metric tension recording.
RNA isolation and cDNA synthesis
Myometrium from time-mated animals and human 
myometrial tissue
Total RNA (tRNA) was isolated from early and late pregnant murine
myometrium (n  6) and term non-labouring (TNL) human myometrial tis-
sue (n  3). Tissue was homogenized using the TissueLyser (Qiagen,
Crawley, UK) in Trizol® (Invitrogen, Paisley, UK) and tRNA extracted as per
manufacturers recommendations. Samples were quantified using the
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Labtech,
Ringmer, UK). cDNA was synthesized from 500 ng tRNA, using 0.25 g
random hexanucleotide primers (Promega, Southampton, UK) and 200 IU
Superscript III (Invitrogen).
Myometrium from LPS-treated mice
tRNA was extracted using the guanidinium isothiocyanate method (4 M
guanidinium isothiocyanate, 25 mM sodium citrate, 0.5% sarkosyl, and 
0.1 M -mercaptoethanol). Caesium chloride (0.4 g/ml homogenate) was
added and samples centrifuged (20 min., 9200  g). The supernatant was
layered onto 1 ml of 5.7 M CsCl cushion (plus 0.1 M ethylenediaminete-
traacetic acid [EDTA], 25 mM sodium acetate) and centrifuged overnight 
at 30,000 rpm (Beckman Coulter Optima LE-80k ultracentrifuge, Brea, CA,
USA; SW 55 Ti rotor). The RNA pellet was ethanol-precipitated and resus-
pended in Tris-EDTA (pH 6.5). cDNA was synthesized using the iScript kit
(Bio-Rad, Hercules, CA, USA).
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Conventional PCR
PCR was carried out on cDNA using Illustra hot start mastermix (GE
Healthcare, Chalfont St Giles, UK) using the PCR primers described in Table 1
(initial denaturation: 95	C for 5 min.; cycling: 94	C for 1 min., 60	C for 
30 sec., 72	C for 1 min. for a total of 35 cycles, with a final extension at 72	C
for 10 min.). Samples were run on 2% agarose gels stained with SYBR safe
(Invitrogen) and visualized using GeneSnap software on a G-BOX system
(Syngene, Cambridge, UK).
Quantitative RT-PCR
Real-time PCR was carried out with the use of SYBR Green chemistry
(Bioline, London, UK) on a RotorGene 6000 (Qiagen, Crawley, UK) using the
primers as listed in Table 1. A pre-PCR cycle was run for 15 min. at 95	C fol-
lowed by 45 cycles of 95	C for 20 sec., 60	C for 20 sec. and 72	C for 20 sec.
followed by a final extension at 72	C for 15 sec. Melt-curve analysis was 
performed to confirm the presence of one single product and non-template
controls run to assess contamination. Cycle threshold values were used for
analysis and abundance data were obtained by the use of quantified cDNA to
generate a standard curve. Standards were quantified using absorbance and
10-fold serial dilutions (1010 to 10 copies) run in parallel with the samples.
Abundance data for the genes of interest were expressed relative to the two
most stable housekeeping genes from a panel of five using GeNorm software
[15]. In early pregnant tissues, the housekeepers used for final analysis were
-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and
GAPDH and 2-microglobulin were used for late pregnant tissues.
Isometric tension recording
For both mouse and human protocols, small longitudinal myometrial strips 
(5 mm  2 mm  2 mm) were mounted and maintained at 37	C, pH 7.4 in
organ baths (oxygenated – 95% O2, 5% CO2) physiological salt solution
(PSS, pH 7.4 in mM: NaCl 119, KCl 4.7, MgSO4 1.17, NaHCO3 25, KH2PO4
1.18, EDTA 0.025, glucose 6 and CaCl2 2.5). Early pregnant strips were 
subjected to 12.75 mN of tension, late pregnant to 14.72 mN and human
myometrial strips to 38.25 mN (approximately 1.5 times original length). After
development of spontaneous contractile activity with a stable baseline (mouse
40 min., human 1–2 hrs). A baseline period of contractile activity was
recorded, before the addition of either XE991 (Tocris Bioscience, Bristol, UK,
1–10 M, broad-spectrum Kv7 channel inhibitor), chromanol 293B (Tocris
Bioscience, 1–30 M, preferential inhibitor of KCNQ1 containing complexes,)
or retigabine/flupirtine (20 M, Kv7 channel activator). Retigabine (20 M)
and XE991 (10 M) were also added to oxytocin (OT, 109 M) augmented
contractions. Time- and gestation-matched control experiments using appro-
priate vehicles [dimethylsulfoxide (DMSO) for retigabine, flupirtine and chro-
manol 293B; H2O for XE991; PSS for OT] were carried out in parallel.
Contractility data were obtained using MacLab™ hardware and analysed
using Chart v4.2 software (ADI Instruments, Chalgrove, UK). Contractile
periods were assessed using mean integral tension (MIT), the sum of the
integrals for each contraction divided by the duration of the period assessed.
All treatment data were then expressed as a percentage of the preceding
baseline periods (MIT as% of baseline period). The frequency of contractions
was also assessed.
Statistical analysis
Relative abundance data were analysed (Stata version 9.2 StataCorp,
College Station, TX, USA), using generalized estimating equations with
semi-robust standard errors for each group: KCNQ or KCNE [16]. Overall
tests for differences between early and late gestation were carried out
using repeated measures ANOVA (RM ANOVA. LPS data were analysed using
Mann–Whitney U-test and summary data presented as medians
(min–max). The Student’s t-test was used to assess isometric tension
recording. Data were expressed as mean  standard error. P  0.05 was
considered significant. ‘n’ refers to the number of animals or human beings
unless otherwise stated.
Results
KCNQ/KCNE expression in myometrium 
from pregnant mice
The presence of KCNQ isoforms in pregnant mouse myometrium
was established by qRT-PCR (Fig. 1A). In early pregnant mouse
myometrium, the relative abundance of mRNA expression was
KCNQ3 
 KCNQ4 
 KCNQ5 
 KCNQ1 
 KCNQ2 (Fig. 1A, P 
0.001). In contrast, in late pregnant mouse myometrium, the rel-
ative abundance was KCNQ1 
 KCNQ5 
 KCNQ4 
 KCNQ3 

KCNQ2 (Fig. 1A P  0.001). Figure 1 also clearly shows that
KCNQ1, 2, 4 and 5 are suppressed in early compared to late preg-
nant tissue (P  0.001) and non-pregnant tissue (P  0.01, com-
pared to data from McCallum et al.). KCNQ3 expression was
higher in non-pregnant tissues (P  0.01) and early pregnant tis-
sues compared to late pregnant tissues (Fig. 1A).
Transcripts for all KCNE genes (Fig. 1B) were detected in
myometrium from early and late pregnant mice. The relative 
abundance of KCNE gene expression in early pregnancy was as
follows: KCNE4 
 KCNE5 
 KCNE2 
 KCNE1 
 KCNE3 (P 
0.001). In late gestational samples the abundance was: KCNE4

 KCNE2 
 KCNE5 
 KCNE1 
 KCNE3 (P  0.001). There was
clear regulation of KCNE mRNA over gestation. In early preg-
nancy, KCNE5 was more highly expressed than in late pregnant
tissues and non-pregnant tissues (P  0.001, non-pregnant
data from McCallum et al.) and KCNE3 expression was 
suppressed in late pregnancy (P  0.05). KCNE1 demonstrated
a trend towards a decrease in expression although this was not
statistically significant. KCNE2 expression was increased over
the course of gestation from non-pregnant to late pregnant 
(P  0.01, Fig. 1B). KCNE4 did not appear to be regulated 
with gestation.
Kv7 channel inhibition with XE991 increases
spontaneous myometrial contractions
XE991 (1 M) enhanced contractility in myometrial tissue from
late pregnant animals (MIT increased by 45%; P  0.01), but
there was limited effect on contraction frequency compared to
time-matched vehicle controls (data not shown).
The effect of XE991 (10 M) was more pronounced (Fig. 2A, B).
Mean data (Fig. 2C, D) indicated that XE991 promoted a 
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Gene Primer sequence Amplicon length Gen bank accession number
Mouse
KCNQ1 () 5-ATGCTCTGTGGTGGGGGGTG-3 185 NM_008434
() 5-CTTCTGCCTCTGCTTCTGCTGG-3
KCNQ2 () 5-TGACCACTTTGACACCTACGCAGA-3 150 NM_008434
() 5-GGAAGAGCAAAGAACGAGACACCA-3
KCNQ3 () 5-CTTCCATATCGACCCCTTCCAACA-3 144 AB000504
() 5-GCGCTTGAAACAGCCAGTGG-3
KCNQ4 () 5-ATGGGGCGCGTAGTCAAGGT-3 169 BB022155
() 5-GGGCTGTGGTAGTCCGAGGTG-3
KCNQ5 () 5-CGCGTTCGTTTTTCTCCTTGTG-3 199 AF249747
() 5-CCTCAGTCTTCCTTGCCATCCTCT-3
KCNE1 () 5-TTCCTCCAGCAACTGACTGCC-3 162 AF263836
() 5-TGGCCAGAAAGGGCAGAACA-3
KCNE2 () 5-TATGGACAGCTGGAGGAGGAACAC-3 133 NM_008424
() 5-GGCCACCACGATGAACGAGA-3
KCNE3 () 5-GTCACTGTGGGCAGTCTCATCC-3 82 NM_134110
() 5-CGTAGTACACATGATAGGGGTCACTACG-3
KCNE4 () 5-AGGCTGTGGGGGGAGGCTAT-3 175 NM_020574
() 5-GGTGCACATCAGGAGAGGAGGAC-3
KCNE5 () 5-ATGAACTGCAGCGAGAGCCAAC-3 173 NM_021342
() 5-TCGTTACCCTTGGCGCTGGT-3
GAPDH () 5-TTGATGGCAACAATCTCCAC-3 110 NM_001001303
() 5-CGTCCCGTAGACAAAATGGT-3
2M () 5-TTCAGTATGTTCGGCTTCCC-3 103 NM_009735
() 5-TGGTGCTTGTCTCACTGACC-3
ARBP () 5-GATGCCCAGGGAAGACAG-3 90 NM_007475.2
() 5-ACAATGAAGCATTTTGGATAATCA-3
-Actin () 5-ATGGAGGGGAATACAGCCC-3 149 NM_007393
() 5-TTCTTTGCAGCTCCTTCGTT-3
B-Gluc () 5-CTCTGGTGGCCTTACCTGAT-3 73 NM_010368.1
() 5-CAGTTGTTGTCACCTTCACCTC-3
Human
KCNQ1 () 5-CATCACCCACATCTCACAGC-3 124 NM_000218.2
() 5-GTCCCGCACATCGTAAGG-3
Table 1 List of primers used for qRT-PCR
Continued
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significant increase in MIT of 70% (compared to vehicle control, 
Fig. 2C, P  0.05) in early pregnant mouse myometrium. This
effect was larger in tissues taken from late pregnant animals
(160% greater than gestation matched vehicle controls, P  0.01,
Fig. 2D). XE991 also increased contraction frequency (by 50% in
early gestation, P  0.01, versus vehicle control) and 100% in late
gestation (P  0.01) (data not shown). In contrast, application of
C293B (1–30 M) had no effect on myometrial contractility in tis-
sues from late pregnant animals (n  8–10, data not shown).
Flupirtine and retigabine suppress myometrial
contractility
Application of flupirtine (20 M) reduced myometrial contractility
in both early and late pregnant mouse myometrial tissues, an
effect that was reversed by XE991 (10 M, Fig. 3A, B). The effect
of flupirtine was significantly greater in myometrium from late
gestation compared to early gestation (P  0.05). In ~40% of late
pregnant myometrial strips flupirtine completely abolished
myometrial contractions. This effect was not observed in any tis-
sues from early pregnant animals.
Similarly, retigabine (20 M), a structurally distinct analogue
of flupirtine, suppressed late pregnant myometrial contractility
(40%, P  0.01) when compared to vehicle control (Fig. 4A, B)
and the effect was reversed by addition of XE991 (10 M).
Retigabine also reduced contraction frequency by 35% (P 
0.01). Retigabine effectively abolished all myometrial contractions
in ~70% of late pregnant tissue strips.
The effect of retigabine and XE991 on agonist
driven contractions
Application of retigabine (20 M) resulted in a decrease in the fre-
quency, amplitude and basal tone of oxytocin (109 M) driven
© 2011 The Authors
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Gene Primer sequence Amplicon length Gen bank accession number
KCNQ2 () 5-GACAAGGACCGCACCAAG-3 123 NM_004518.3
() 5-CACCAGGAAGTCCAGCTTCT-3
KCNQ3 () 5-CGAGTTTGCTTTGAGGATCTG-3 119 NM_004519.2
() 5-AGGCAATCAGCACAAAGATGT-3
KCNQ4 () 5-TGCCCCCTCAGAGGAAGT-3 119 NM_004700.2
() 5-CCACCAGGAACTTGAGAATCC-3
KCNQ5 () 5-AGTCCCACCAAAGTGCAGA-3 120 NM_019842.2
() 5-AGTGCCAAGGGCTGTGTC-3
Table 1 Continued
Fig. 1 Expression of (A) KCNQ and (B) KCNE genes in non-pregnant,
early and late pregnant mouse myometrial tissue. Non-pregnant
(oestrous, white bars, n  6; data taken from McCallum et al., for com-
parison), early pregnant (black bars, n  6, gestation days 6–7) and late
pregnant mouse myometrium (grey bars, n  6, gestation days 17–18).
Data are expressed as log geometric mean of copy number ( S.E.) nor-
malized to housekeeping genes. (* P  0.001,  P  0.01, P  0.05).
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contractions (Fig. 4C). MIT was suppressed by ~80% (P  0.05
compared to OT period, Fig. 4D) and contraction frequency was
reduced by 50% (data not shown) although this did not quite
reach significance. Inhibition of Kv7 channels with XE991 (10 M)
on oxytocin-driven contractions reduced the basal tone and ampli-
tude and MIT (mean  S.E.: 171.2  22.9% versus 94.9 
22.4%; P  0.05). There was no effect on contraction frequency
(mean  S.E.: 126.7  11.5% versus 123.7  14.4%).
The impact of LPS treatment on myometrial
KCNQ/KCNE expression
KCNQ and KCNE mRNA was detected in myometrium from LPS-
treated mice at 8 hrs after injection. There was a generalized sup-
pression of most of the KCNQ/KCNE isoforms compared to
myometrium taken from vehicle-treated control mice (Fig. 5A, B,
P  0.05), with the exception of KCNQ4 and KCNE5.
The expression and function of Kv7 channels 
in human myometrial smooth muscle
Figure 6(A) and (B) clearly shows that all KCNQ isoforms with the
exception of KCNQ5 are expressed in human myometrial smooth
muscle tissue. RT-PCR data suggest that KCNQ4 and KCNQ1 are
the most abundant -subunit isoforms. The channels encoded by
these genes are functional in late pregnant human myometrial
smooth muscle as Kv7 channel modulators have a significant
impact on myometrial contractility (Fig. 6C, D). Application of 
10 M XE991 (7C) increased the frequency of spontaneous
myometrial contractions by 219% whereas retigabine (n  3, 
20 M) relaxed human myometrial tissues (n  3, MIT decreased
by 50% compared to vehicle controls, Fig. 6D).
Discussion
These data clearly demonstrate, for the first time, a significant
functional impact of Kv7 channels in pregnant mouse and human
myometrium. The observation that the majority of mouse KCNQ
isoforms are most highly expressed in late pregnancy and are not
regulated by a generalized inflammatory response in mice sug-
gests that Kv7 channels may ultimately represent novel targets for
therapy in relation to pregnancy disorders such as preterm labour.
The profound relaxation induced by Kv7 channel activators in vitro
in human tissues is particularly important, as the activator retiga-
bine (currently in phase III clinical trials [17]) has been used safely
in human beings for the treatment of non-reproductive disorders
© 2011 The Authors
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Fig. 2 Effect of XE991 (10 M)
on spontaneous myometrial
contractions in tissues from
mice in early (A) and late
pregnancy (B). (C) Mean
effect of XE991 (10 M)
(S.E.) in early pregnancy 
(n  10 from 9 animals) 
versus vehicle control (n  10
from 9 animals). (D) Mean
effect of XE991 (10 M)
(S.E.) in late pregnancy 
(n  14 from 8 animals) com-
pared to vehicle controls (n 
14 from 8 animals). (* P 
0.05, ** P  0.01).
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and flupirtine has been licensed in some countries for use as an
analgesic [18].
All KCNQ and KCNE isoforms were expressed in mouse
myometrium in early and late gestation, but the majority of KCNQ
isoforms were up-regulated in late pregnancy. This contrasts to
published data on other K channels -subunits including
ROMK1 [19], Kv4.1 and 4.3 [20], KATP, and SK3 [14, 21] which
decrease in expression with gestation.
© 2011 The Authors
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Fig. 3 The effect of flupirtine
(20 M) on spontaneous
myometrial contractions from
mice in early (A) and late
pregnancy (B). The impact of
flupirtine (20 M, mean 
S.E.) and reversal by XE991
(10 M) in myometrium from
animals in early (C, n  6)
and late pregnancy (D, n  10
from 9 animals) compared to
time and gestation-matched
vehicle controls (C, n  6; 
D, n  9 from 8 animals). 
(* P  0.05, ** P  0.01,
*** P  0.001).
Fig. 4 The effect of retigabine
(20 M) on spontaneous (A)
and oxytocin induced (109
M, C) myometrial contrac-
tions in tissue from mice in
late pregnancy. (B); mean
data (S.E.) for retigabine
(20 M) and reversal by
XE991 (10 M, n  10 from
9 animals) compared to vehi-
cle controls (n  9 from 8
animals). (D); Mean ( S.E.)
for retigabine versus oxytocin
period (n  3). (* P  0.05,
** P  0.01, *** P  0.001).
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It is apparent from our data that KCNQ1 containing complexes,
similar to those found in the heart, are non-functional in mouse
myometrium as chromanol (potent inhibitor of these complexes at
low concentrations) had no effect on myometrial activity. This
could be partially attributed to the co-assembly of KCNQ1 with
KCNE4 as this is known to inhibit the K current through KCNQ1
encoded channels [22]. Indeed preliminary co-immunoprecipita-
tion data from our lab indicates that these two subunits may inter-
act. The lower expression levels of most KCNQ mRNA in early
pregnancy were supported by functional data as the activator
flupirtine could only partially suppress myometrial contractions in
early pregnant animals. In late pregnant animals both flupirtine
and retigabine entirely suppressed contractile activity in 40% and
70% of tissues studied, respectively.
In contrast, to other isoforms, KCNQ3 expression was highest
in early pregnancy, potentially indicating a contribution of this iso-
form to resting cell excitability. In neurones, KCNQ3 is the under-
lying constituent of the M current when in multimeric combination
with KCNQ2 [23]. The M-current is a non-inactivating potassium
current involved in subthreshold activity in many neuronal cell
types. Due to the low KCNQ2 expression throughout pregnancy in
myometrium, formation of this complex is unlikely. However,
KCNQ5 and KCNQ3 have also been shown to form a multimer that
may contribute to the native M-current [24]. KCNQ3 could also
form multimers with other KCNQ proteins or exist as a non-func-
tional homomeric channel [25].
KCNE isoforms show a different pattern of regulation across
pregnancy to KCNQ genes. A significant increase is seen in KCNE2
mRNA between early and late pregnant myometrium, mirroring
data previously found by our lab in BALBC mice [8]. Conversely,
KCNE3 and KCNE5 appear to be down-regulated in late pregnant
myometrial tissue. KCNE4, is also highly expressed in all tissues
studied throughout gestation, and as discussed earlier may serve
to inhibit KCNQ1 function [22]. Interestingly, all KCNE isoforms
can also associate with KCNQ4 and interactions with KCNE4 in
particular can augment the K current [26].
KCNE isoforms can also associate with non-KCNQ encoded -
subunits [27–34] and our data suggest that KCNE2 may play an
important functional role in inhibiting the ERG current in late preg-
nant mouse myometrium, potentially promoting activation of the
uterine smooth muscle at term [8]. This functional suppression of
ERG currents occurs at the same point in gestation when there is
an up-regulation of a majority of Kv7 channel encoding isoforms.
This strengthens the hypothesis that KCNE isoforms may function
as molecular switches at the end of pregnancy and regulate more
than one Kv gene family in parallel.
The application of the broad-spectrum Kv7 inhibitor XE991 to
myometrial tissue in vitro also demonstrated the key role Kv7
channels play in modulating contractile activity in both early and
late pregnant myometrium, although the effect appeared more
marked in tissues from late gestation.
Our data also demonstrate that Kv7 channels impact on oxy-
tocin-induced contractile activity as XE991 led to a fusion of con-
tractile activity. Significantly, retigabine effectively suppressed
oxytocin induced contractile activity. This is important as oxytocin
may be involved in stimulating contractions during labour.
The use of a generalized model of inflammation in pregnant
mice allowed assessment of the impact of an inflammatory milieu
on myometrial KCNQ/KCNE gene expression. Most of the KCNQ
and KCNE mRNA expression in myometrial tissue, except for
KCNQ4 and KCNE5, was suppressed in tissues from LPS-treated
tissues compared to vehicle controls. This could indicate that
modulation of these channels is associated with the onset of infec-
tion-associated preterm labour. However, quantification of gene
expression would suggest that mRNA levels are still relatively high
and that functional Kv7 channels are likely to be expressed and
contribute to control of uterine activity during preterm labour in
this mouse model.
In human myometrium, taken from women prior to labour
onset at term, all the major KCNQ transcripts are expressed,
except for KCNQ5. The functional contribution of these channels is
© 2011 The Authors
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Fig. 5 The expression of KCNQ (A) and KCNE (B) mRNA transcripts in
myometrial tissue taken from mice 8 hrs after being injected (IP) with
LPS (100 ng). Vehicle control (grey bars, n  3) and LPS (black bars, 
n  4). Data are expressed as log mean of copy number ( S.E.) nor-
malized to geometric mean of two housekeeping genes (* P  0.05).
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illustrated by the relaxation provoked by retigabine and the impact
of XE991 on contractile frequency. These data further strengthen
our proposal for Kv7 channels as targets for development of novel
tocolytics. However, it is essential that the role of Kv7 channels 
in other reproductive tissues also be determined to address 
any potential for adverse influences on maternal and neonatal 
outcome. The expression profile of KCNQ and KCNE genes is dif-
ferent in the uterus from those in heart and brain, but may have
resemblance to vascular and other smooth muscles. The reported
side effects of retigabine and flupirtine to-date are mainly central
nervous system related and reported to be mild [17, 35].
Nifedipine use as a tocolytic is associated with systemic cardio-
vascular effects [36], but these side-effects are not been reported
with treatment with retigabine/flupirtine use in clinical trials/as an
analgesic and would be a distinct benefit.
In summary, the maintained presence of Kv7 channels in the
murine myometrium throughout gestation and the demonstrable
functional impact of Kv7 activators and inhibitors provide clear
evidence for a key role for these channels in regulating rhythmic
myometrial activity at term. Furthermore, given that functional Kv7
channels are present in term human myometrial tissue, then Kv7
channel directed drugs currently in development may represent
novel tocolytics for use in preterm labour.
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Fig. 6 The expression (A) and
function (B–C) of KCNQ iso-
forms in myometrial tissue
from pregnant women at term
(n  3). KCNQ1 (124 bp),
KCNQ2 (123 bp), KCNQ3
(119 bp), KCNQ4 (119 bp),
KCNQ5 (120 bp). The effect of
(B) XE991 (10 M) and (C)
retigabine (20 M) on spon-
taneous myometrial contrac-
tions in vitro (not in labour,
representative of n  3).
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